All In Biotech

Drug Trial Radar · NCT06895928

A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

A Phase II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Mar 28, 2025

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
Mar 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with other antitumor therapies in advanced solid tumors to explore the reasonable dosage, safety and efficacy of SHR-A2102 for advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • SHR-A2102Drug

    SHR-A2102 for injection.

  • Bevacizumab InjectionDrug

    Bevacizumab injection.

  • Adebelimab InjectionDrug

    Adebelimab injection.

  • Ametinib Mesylate TabletsDrug

    Ametinib mesylate tablets.

  • Osimertinib Mesylate TabletsDrug

    Osimertinib mesylate tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AEs)Time frame: From day 1 to 90 days after the last dose.
  2. Serious adverse events (SAEs)Time frame: From day 1 to 90 days after the last dose.
  3. Objective response rate (ORR)Time frame: About 2 years.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanxi Cancer hospital

    Taiyuan, Shanxi, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.